Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 21, 2026, 8:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Discontinue Clopidogrel Clear all

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Eltrombopag, Avatrombopag, Standard of care; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Watertown, South Dakota

Conditions: Atherosclerosis, Percutaneous Coronary Intervention, Acute Coronary Syndrome
Interventions: cangrelor P2Y12 (platelet) inhibitor, Clopidogrel - 300 or 600 mg (study arm), Clopidogrel 600 mg post cangrelor; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 11,145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Anderson, South Carolina

Conditions: Blood Platelets, Clopidogrel
Interventions: clopidogrel + aspirin, placebo, Aspirin; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 21 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Coronary Artery Disease
Interventions: Prasugrel, Clopidogrel; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: La Jolla, California • Jacksonville, Florida • Cincinnati, Ohio + 1 more

Conditions: Non-Valvular Atrial Fibrillation, Left Atrial Appendage Closure
Interventions: Edoxaban, WATCHMAN LAA Closure, Aspirin and Clopidogrel, Aspirin and Warfarin; Drug · Device
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Pseudotumor Cerebri, Idiopathic Intracranial Hypertension (IIH)
Interventions: Dural Venous Sinus Stenting, Cerebrospinal Fluid Shunting; Device
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Phoenix, Arizona • Seattle, Washington

Conditions: Aortic Valve Disorder
Interventions: SAVR Warfarin, SAVR Aspirin, TAVR Warfarin and clopidogrel, TAVR Aspirin and clopidogrel; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Community-acquired Pneumonia, Influenza, COVID-19
Interventions: Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir; Drug · Other · Biological + 1 more
Lead sponsor: UMC Utrecht; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 11
States / cities: Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more

Conditions: Clopidogrel
Interventions: Clopidogrel, Discontinue Clopidogrel; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2, Coronary Artery Disease
Interventions: Ticagrelor monotherapy, Ticagrelor plus aspirin, Clopidogrel with aspirin; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Coronary Artery Disease (CAD)
Interventions: Cangrelor, Clopidogrel, Prasugrel; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Transcatheter Aortic Valve Replacement
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic Acid (ASA), Clopidogrel, Vitamin K antagonist (VKA); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 31
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Clearwater, Florida + 27 more

Search by objective public record fields.

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

PACT (Platelet Activity After Clopidogrel Termination)

Prasugrel/Clopidogrel Maintenance Dose Washout Study

A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure

Operative Procedures Vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial

Frequency of Reduced Leaflet Motion After Surgical Aortic Valve Replacement and Transcatheter Aortic Valve Replacement.

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?

Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus

Cangrelor to Clopidogrel or Prasugrel Transition Study

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes